Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer

Oncotarget

Volumn 8, Issue 19, 2017, Pages 30859-30869

  Monzo, Mariano ^a   Santasusagna, Sandra ^a   Moreno, Isabel ^b   Martinez, Francisco ^b   Hernández, Raquel ^b   Muñoz, Carmen ^a   Castellano, Joan J ^a   Moreno, Josep ^b   Navarro, Alfons ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital Municipal de Badalona   (Spain)

Author keywords

Colon cancer; Exosomes; MicroRNAs; MiR 328; Tumor draining vein

Indexed keywords

MICRORNA; MICRORNA 106B; MICRORNA 126; MICRORNA 142 3P; MICRORNA 155; MICRORNA 15B; MICRORNA 18B; MICRORNA 26A; MICRORNA 328; MICRORNA 410; MICRORNA 449; MICRORNA 548C 5P; MICRORNA 744; MICRORNA LET 7G; UNCLASSIFIED DRUG; CIRCULATING MICRORNA; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; LIVER METASTASIS; MALE; MESENTERIC VEIN; METASTASIS POTENTIAL; PREDICTIVE VALUE; RNA ANALYSIS; CANCER GRADING; COLON TUMOR; EXOSOME; FOLLOW UP; GENE EXPRESSION; GENETICS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CIRCULATING MICRORNA; COLONIC NEOPLASMS; EXOSOMES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECURRENCE;

EID: 85019117855     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16103     Document Type: Article

References (30)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:252-271
2. Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P and Van Cutsem E. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. Journal of clinical oncology. 2004; 22:3408-3419
3. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P and Bridgewater J. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England Journal of Medicine. 2004; 350:2343-2351
4. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K and Schmoll H-J. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Journal of clinical oncology. 2011; 29:1465-1471
5. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE and Francois Seitz J. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Journal of clinical oncology. 2004; 22:1797-1806
6. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem J-L, Thaler J, Bridgewater J, Petersen LN and Blons H. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. The Lancet Oncology. 2014; 15:862-873
7. de Gramont A, Van Cutsem E, Schmoll H-J, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR and Rivera F. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. The Lancet Oncology. 2012; 13:1225-1233
8. Ma Y, Zhang P, Yang J, Liu Z, Yang Z and Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. International journal of cancer. 2012; 130:2077-2087
9. Ng EK, Chong WW, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ. Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut. 2009
10. Schee K, Boye K, Abrahamsen TW, Fodstad Ø and Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC cancer. 2012; 12:505
11. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Annals of surgery. 2014; 259:735
12. Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A and Alajez NM. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Scientific reports. 2016; 6
13. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Di Giannatale A and Ceder S. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527:329-335
14. Milane L, Singh A, Mattheolabakis G, Suresh M and Amiji MM. Exosome mediated communication within the tumor microenvironment. Journal of Controlled Release. 2015; 219:278-294
15. O'Driscoll L. Expanding on exosomes and ectosomes in cancer. New England Journal of Medicine. 2015; 372:2359-2362
16. Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H and Takano Y. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. British journal of cancer. 2015; 113:275-281
17. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H and Sonoda H. Circulating exosomal microRNAs as biomarkers of colon cancer. PloS one. 2014; 9:e92921
18. Monzo M, Martínez-Rodenas F, Moreno I, Navarro A, Santasusagna S, Macias I, Muñoz C, Tejero R and Hernández R. Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients. Medicine. 2015; 94:e145
19. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC and Holsinger LJ. Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nature cell biology. 2014; 16:876-888
20. Crosbie PA, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J, Booton R, Blackhall F and Dive C. Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC. Journal of Thoracic Oncology. 2016; 11:1793-1797
21. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H and Lyden D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell. 2016; 30:836-848
22. Peinado H, Alekovi M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G and Ghajar CM. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nature medicine. 2012; 18:883-891
23. de la Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T, Lopez-Lopez R and Abal M. M-trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. Journal of the National Cancer Institute. 2015; 107:djv184
24. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A and Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PloS one. 2009; 4:e6229
25. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J and Quindós M. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. Journal of translational medicine. 2012; 10:186
26. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM and Sibenaller Z. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. International journal of cancer. 2011; 129:2621-2631
27. Koppe MJ, Boerman OC, Oyen WJ and Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Annals of surgery. 2006; 243:212-222
28. Navarro A, Díaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, Magnano L, Rosiñol L, Monzó M and Bladé J. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015; 6:1874-83. doi: 10.18632/oncotarget.2761
29. Wright GW and Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics. 2003; 19:2448-2455
30. Ruiz-Martinez M, Navarro A, Marrades RM, Viñolas N, Santasusagna S, Muñoz C, Ramírez J, Molins L and Monzo M. YKT6 expression, exosome release, and survival in nonsmall cell lung cancer. Oncotarget. 2016; 7:51515-51524. doi: 10.18632/oncotarget.9862